Research Article
BibTex RIS Cite

Do sodium glucose co-transporter-2 (sglt-2) inhibitors affect lower urinary tract, sleep and quality of life in people with type 2 diabetes?

Year 2024, Volume: 8 Issue: 3, 660 - 667, 30.09.2024
https://doi.org/10.30621/jbachs.1497286

Abstract

Purpose: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are primarily preferred in patients with type 2 diabetes. The purpose of this paper was to elucidate the effects of SGLT-2 inhibitor use on patients' voiding habits, sleep, and quality of life.
Methods: Our study involved patients with type 2 diabetes who had an SGLT2 inhibitor added to their current treatment. The frequency of day-night urination, lower urinary tract symptoms, sleep and quality of life were assessed both prior to initiation of the treatment and during subsequent 1st and 3rd months.
Results: The study included 38 women and 34 men. At the third month after SGLT-2 inhibitor had been added, there was a significant decrease in HbA1c, triglyceride and microalbumin levels (p<0.05). There was no increase in voiding frequency (day/night) and there was no difference in the evaluation of lower urinary tract symptoms, but voiding volumes increased in uroflowmetry. When the short form-36 (SF-36) scale was examined, there was a significant improvement in physical function, one of the sub-parameters (p = 0.01). The factor affecting this most, was the improvement in HbA1c.
Conclusion: This paper suggests that SGLT-2 inhibitors don’t increase voiding frequency and don’t cause an increase in lower urinary tract symptoms.

References

  • American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care 2014;37 Suppl 1:S14-S80.
  • Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012;2(5):e001007.
  • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373(22):2117-2128.
  • Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;377(7):644-657.
  • Shikuma J, Ito R, Sasaki‐Shima J, et al. Changes in overactive bladder symptoms after sodium glucose cotransporter‐2 inhibitor administration to patients with type 2 diabetes. Practical Diabetes 2018 Mar;35(2):47-50.
  • Şahin S, Haliloğlu Ö, Polat Korkmaz Ö, et al. Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus? Turk J Med Sci 2020;51(2):735-742.
  • Gungor F, Yasa C, Yuksel Ozgor B, et al. Validation of the Turkish version of the ICIQ-FLUTS, ICIQ-FLUTS long-form, ICIQ-LUTS quality-of-life, and ICIQ-FLUTS sexual functions. Neurourol Urodyn 2020;39(3):962-968.
  • Mertoğlu O, Üçer O, Ceylan Y, et al. Reliability and Validity of the Turkish Language Version of the International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptoms. Int Neurourol J 2016;20(2):159-163.
  • Kocyiğit H, Aydemir O, Fisek G, Olmez N, Memiş A. Kısa Form- 36 (KF-36)’nın Turkce versiyonunun guvenilirliği ve gecerliliği. İlac ve Tedavi Dergisi 1999; 12:102- 6.
  • Abraham L, Hareendran A, Mills IW, et al. Development and validation of a quality-of-life measure for men with nocturia. Urology 2004;63(3):481-486.
  • Izci B, Ardic S, Firat H, Sahin A, Altinors M, Karacan I. Reliability and validity studies of the Turkish version of the Epworth Sleepiness Scale. Sleep Breath 2008;12(2):161-168.
  • Dekkers CCJ, Gansevoort RT, Heerspink HJL. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. Curr Diab Rep 2018;18(5):27.
  • Chilelli NC, Bax G, Bonaldo G, et al. Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors-overlooked and overwhelming? A retrospective case series. Endocrine 2018;59(3):690-693.
  • Kabadi UM. SGLT2 inhibitors: far too many cautions and alerts and limited efficacy. J Diabetes Metab Disord Control 2016;3(5):90-94.
  • Guo Z, Wang L, Yu J, Wang Y, Yang Z, Zhou C. The role of SGLT-2 inhibitors on health-related quality of life, exercise capacity, and volume depletion in patients with chronic heart failure: a meta-analysis of randomized controlled trials [published correction appears in Int J Clin Pharm 2023;45(3):547-555.
  • Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev 1999;15(3): 205-218.
  • Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep 2017;7(1):2824.
Year 2024, Volume: 8 Issue: 3, 660 - 667, 30.09.2024
https://doi.org/10.30621/jbachs.1497286

Abstract

References

  • American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care 2014;37 Suppl 1:S14-S80.
  • Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012;2(5):e001007.
  • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373(22):2117-2128.
  • Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;377(7):644-657.
  • Shikuma J, Ito R, Sasaki‐Shima J, et al. Changes in overactive bladder symptoms after sodium glucose cotransporter‐2 inhibitor administration to patients with type 2 diabetes. Practical Diabetes 2018 Mar;35(2):47-50.
  • Şahin S, Haliloğlu Ö, Polat Korkmaz Ö, et al. Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus? Turk J Med Sci 2020;51(2):735-742.
  • Gungor F, Yasa C, Yuksel Ozgor B, et al. Validation of the Turkish version of the ICIQ-FLUTS, ICIQ-FLUTS long-form, ICIQ-LUTS quality-of-life, and ICIQ-FLUTS sexual functions. Neurourol Urodyn 2020;39(3):962-968.
  • Mertoğlu O, Üçer O, Ceylan Y, et al. Reliability and Validity of the Turkish Language Version of the International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptoms. Int Neurourol J 2016;20(2):159-163.
  • Kocyiğit H, Aydemir O, Fisek G, Olmez N, Memiş A. Kısa Form- 36 (KF-36)’nın Turkce versiyonunun guvenilirliği ve gecerliliği. İlac ve Tedavi Dergisi 1999; 12:102- 6.
  • Abraham L, Hareendran A, Mills IW, et al. Development and validation of a quality-of-life measure for men with nocturia. Urology 2004;63(3):481-486.
  • Izci B, Ardic S, Firat H, Sahin A, Altinors M, Karacan I. Reliability and validity studies of the Turkish version of the Epworth Sleepiness Scale. Sleep Breath 2008;12(2):161-168.
  • Dekkers CCJ, Gansevoort RT, Heerspink HJL. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. Curr Diab Rep 2018;18(5):27.
  • Chilelli NC, Bax G, Bonaldo G, et al. Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors-overlooked and overwhelming? A retrospective case series. Endocrine 2018;59(3):690-693.
  • Kabadi UM. SGLT2 inhibitors: far too many cautions and alerts and limited efficacy. J Diabetes Metab Disord Control 2016;3(5):90-94.
  • Guo Z, Wang L, Yu J, Wang Y, Yang Z, Zhou C. The role of SGLT-2 inhibitors on health-related quality of life, exercise capacity, and volume depletion in patients with chronic heart failure: a meta-analysis of randomized controlled trials [published correction appears in Int J Clin Pharm 2023;45(3):547-555.
  • Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev 1999;15(3): 205-218.
  • Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep 2017;7(1):2824.
There are 17 citations in total.

Details

Primary Language English
Subjects Endocrinology
Journal Section Research Article
Authors

Gökçen Güngör Semiz 0000-0002-8915-9178

Ege Sarıkaya This is me 0000-0001-7247-1416

Mehmet Emin Arayıcı 0000-0002-0492-5129

Ozan Bozkurt 0000-0002-7662-0092

Serkan Yener 0000-0003-0427-735X

Tevfik Demir 0000-0003-0319-9572

Publication Date September 30, 2024
Submission Date June 13, 2024
Acceptance Date September 17, 2024
Published in Issue Year 2024 Volume: 8 Issue: 3

Cite

APA Güngör Semiz, G., Sarıkaya, E., Arayıcı, M. E., Bozkurt, O., et al. (2024). Do sodium glucose co-transporter-2 (sglt-2) inhibitors affect lower urinary tract, sleep and quality of life in people with type 2 diabetes?. Journal of Basic and Clinical Health Sciences, 8(3), 660-667. https://doi.org/10.30621/jbachs.1497286
AMA Güngör Semiz G, Sarıkaya E, Arayıcı ME, Bozkurt O, Yener S, Demir T. Do sodium glucose co-transporter-2 (sglt-2) inhibitors affect lower urinary tract, sleep and quality of life in people with type 2 diabetes?. JBACHS. September 2024;8(3):660-667. doi:10.30621/jbachs.1497286
Chicago Güngör Semiz, Gökçen, Ege Sarıkaya, Mehmet Emin Arayıcı, Ozan Bozkurt, Serkan Yener, and Tevfik Demir. “Do Sodium Glucose Co-Transporter-2 (sglt-2) Inhibitors Affect Lower Urinary Tract, Sleep and Quality of Life in People With Type 2 Diabetes?”. Journal of Basic and Clinical Health Sciences 8, no. 3 (September 2024): 660-67. https://doi.org/10.30621/jbachs.1497286.
EndNote Güngör Semiz G, Sarıkaya E, Arayıcı ME, Bozkurt O, Yener S, Demir T (September 1, 2024) Do sodium glucose co-transporter-2 (sglt-2) inhibitors affect lower urinary tract, sleep and quality of life in people with type 2 diabetes?. Journal of Basic and Clinical Health Sciences 8 3 660–667.
IEEE G. Güngör Semiz, E. Sarıkaya, M. E. Arayıcı, O. Bozkurt, S. Yener, and T. Demir, “Do sodium glucose co-transporter-2 (sglt-2) inhibitors affect lower urinary tract, sleep and quality of life in people with type 2 diabetes?”, JBACHS, vol. 8, no. 3, pp. 660–667, 2024, doi: 10.30621/jbachs.1497286.
ISNAD Güngör Semiz, Gökçen et al. “Do Sodium Glucose Co-Transporter-2 (sglt-2) Inhibitors Affect Lower Urinary Tract, Sleep and Quality of Life in People With Type 2 Diabetes?”. Journal of Basic and Clinical Health Sciences 8/3 (September 2024), 660-667. https://doi.org/10.30621/jbachs.1497286.
JAMA Güngör Semiz G, Sarıkaya E, Arayıcı ME, Bozkurt O, Yener S, Demir T. Do sodium glucose co-transporter-2 (sglt-2) inhibitors affect lower urinary tract, sleep and quality of life in people with type 2 diabetes?. JBACHS. 2024;8:660–667.
MLA Güngör Semiz, Gökçen et al. “Do Sodium Glucose Co-Transporter-2 (sglt-2) Inhibitors Affect Lower Urinary Tract, Sleep and Quality of Life in People With Type 2 Diabetes?”. Journal of Basic and Clinical Health Sciences, vol. 8, no. 3, 2024, pp. 660-7, doi:10.30621/jbachs.1497286.
Vancouver Güngör Semiz G, Sarıkaya E, Arayıcı ME, Bozkurt O, Yener S, Demir T. Do sodium glucose co-transporter-2 (sglt-2) inhibitors affect lower urinary tract, sleep and quality of life in people with type 2 diabetes?. JBACHS. 2024;8(3):660-7.